HIV-TB合并感染患者中利福平与异烟肼的药代动力学:ANRS12292-RIFAVIRENZ子研究
结果显示利福平剂量加倍使Cmax和AUClast增加近3倍,加用依非韦伦使利福平AUClast降低34%-40%,异烟肼AUClast在依非韦伦600 mg时不受影响但800 mg时降低23%。结论强调调整利福平剂量以达到治疗水平的重要性,依非韦伦对利福平和异烟肼药代动力学影响轻微且无临床意义。
要点
- 利福平剂量加倍(20 mg/kg/天)使Cmax和AUClast增加近3倍,87%患者达到治疗浓度。
- 加用依非韦伦使利福平AUClast降低34%-40%,异烟肼AUClast在依非韦伦800 mg时降低23%。
- 依非韦伦增加乙酰异烟肼浓度,提示乙酰化活性增强。
核心结论
- 在HIV-TB合并感染患者中,利福平剂量加倍可提高Cmax在治疗范围内的患者比例。
- 依非韦伦对利福平和异烟肼药代动力学有轻微影响,但无临床显著性,支持联合方案的有效性和安全性。
研究设计与样本
- 比较两种利福平剂量(10和20 mg/kg/天)及依非韦伦剂量(600和800 mg q24h)下的药代动力学参数。
主要发现
- 利福平剂量加倍使Cmax和AUClast增加近3倍。
- 加用依非韦伦使利福平AUClast降低34%-40%。
- 异烟肼AUClast在依非韦伦600 mg q24h时不受影响,在800 mg q24h时降低23%。
- 依非韦伦增加乙酰异烟肼浓度,提示乙酰化活性增强。
- 利福平10 mg/kg时,88%患者Cmax低于治疗范围;20 mg/kg时,87%患者达到治疗浓度。
关键数值与推荐
- 药代动力学比较采用几何均值比、90% CI和预设的0.80-1.25区间。
- 利福平剂量10 mg/kg/天时,88%患者Cmax低于治疗范围;20 mg/kg/天时,87%患者达到治疗浓度。
临床怎么用
- 在HIV-TB合并感染患者中,建议调整利福平剂量至20 mg/kg/天以提高达到治疗浓度的比例。
- 依非韦伦600或800 mg q24h与利福平联用时,药代动力学变化无临床显著性,可支持联合用药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increasing rifampicin dosing is considered a potent strategy for shortening TB treatment duration. Although previous data among patients with HIV-TB coinfection has shown that doubling rifampicin dosing had a small effect on EFV concentrations, its effect on the pharmacokinetics (PK) of antituberculosis drugs remains lacking in this population. OBJECTIVES: To compare the PK of rifampicin and isoniazid with and without EFV co-administration in patients with HIV-TB coinfection using two rifampicin dosing regimens (10 and 20 mg/kg/day) and EFV dosing (600 and 800 mg q24h). METHODS: Ninety-seven patients were assigned to three arms in a randomized clinical trial conducted in Uganda. Plasma concentrations of rifampicin, isoniazid, and acetyl-isoniazid were measured. PK parameters were estimated, and statistical comparisons were made using geometric mean ratios, 90% CIs and the pre-set 0.80-1.25 interval. RESULTS: Doubling rifampicin dosing increased its Cmax and AUClast almost 3-fold. Adding EFV decreased rifampicin AUClast by 34%-40%. Isoniazid AUClast was unaffected with EFV 600 mg q24h but decreased with EFV 800 mg q24h by 23%. EFV increased acetyl-isoniazid concentrations, suggesting enhanced acetylation activity. At 10 mg/kg of rifampicin, 88% of patients had Cmax below the therapeutic range. However, at 20 mg/kg of rifampicin, 87% of patients achieved therapeutic concentrations, ensuring effective treatment. CONCLUSIONS: The study highlights the importance of adjusting rifampicin dosing to achieve therapeutic levels in patients with coinfection. Doubling rifampicin dosing in patients with HIV-TB coinfection increases the percentage of patients with Cmax within the therapeutic range. Additionally, while EFV slightly affects rifampicin and isoniazid PK, these changes are not clinically significant, supporting the efficacy and safety of the combined regimen.
引用
- Gelé T, Atwine D, Baudin E, et al. Pharmacokinetics of rifampicin and isoniazid in patients with HIV-tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292-RIFAVIRENZ sub-study. J Antimicrob Chemother. 2025. PMID: 40879459. doi:10.1093/jac/dkaf319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。